Iron metabolism disturbance in a French cohort of ALS patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Veyrat Durebex, Charlotte ^a,b   Corcia, Philippe ^a,c   Mucha, Aleksandra ^b   Benzimra, Simon ^b   Mallet, Cindy ^b   Gendrot, Chantal ^b   Moreau, Caroline ^d   Devos, David ^d   Piver, Eric ^e   Pagès, Jean Christophe ^e   Maillot, François ^c   Andres, Christian R ^a,b   Vourc'H, Patrick ^a,b   Blasco, Hélène ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FERRITIN; IRON; TRANSFERRIN;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; FORCED VITAL CAPACITY; GLOMERULUS FILTRATION RATE; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; IRON METABOLISM DISORDER; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; RATING SCALE; RISK FACTOR; SEX RATIO; SURVIVAL; TRANSFERRIN BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; FRANCE; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; FERRITINS; FRANCE; HUMANS; IRON; MALE; MIDDLE AGED; RISK FACTORS; TRANSFERRIN;

EID: 84904619548     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/485723     Document Type: Article

References (43)

1. van Blitterswijk M., van Es M. A., Hennekam E. A. M., Dooijes D., van Rheenen W., Medic J., Bourque P. R., Schelhaas H. J., van der Kooi A. J., de Visser M., de Bakker P. I. W., Veldink J. H., van den Berg L. H., Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Human Molecular Genetics 2012 21 17 3776 3784 10.1093/hmg/dds199 2-s2.0-84865071988
2. Shaw P. J., Molecular and cellular pathways of neurodegeneration in motor neurone disease. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 8 1046 1057 10.1136/jnnp.2004.048652 2-s2.0-23144448320 (Pubitemid 41081274)
3. Jenner P., Clues to the mechanism underlying dopamine cell death in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1989 52 22 28 10.1136/jnnp.52.Suppl.22 2-s2.0-0024474829 (Pubitemid 19167878)
4. Bush A. I., The metal theory of Alzheimer's disease. Journal of Alzheimer's Disease 2013 33 supplement 1 S277 S281 10.3233/JAD-2012-129011 2-s2.0-84872562074
5. Oba H., Araki T., Ohtomo K., Monzawa S., Uchiyama G., Koizumi K., Nogata Y., Kachi K., Shiozawa Z., Kobayashi M., Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993 189 3 843 846 2-s2.0-0027429573 (Pubitemid 23354505)
6. Kasarskis E. J., Tandon L., Lovell M. A., Ehmann W. D., Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. Journal of the Neurological Sciences 1995 130 2 203 208 10.1016/0022-510X(95) 00037-3 2-s2.0-0029017315
7. Ignjatovic A., Stevic Z., Lavrnic S., Dakovic M., Bacic G., Brain iron MRI: a biomarker for amyotrophic lateral sclerosis. Journal of Magnetic Resonance Imaging 2013 38 6 1472 1479 10.1002/jmri.24121
8. Suh Y. J., Rathore K. I., Schulz K., Ponka P., Arosio P., David S., Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience 2009 29 3 610 619 10.1523/JNEUROSCI.5443-08.2009 2-s2.0-58849116869
9. Goodall E. F., Haque M. S., Morrison K. E., Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. Journal of Neurology 2008 255 11 1652 1656 10.1007/s00415-008-0945-0 2-s2.0-58549088290
10. Mitchell R. M., Simmons Z., Beard J. L., Stephens H. E., Connor J. R., Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle and Nerve 2010 42 1 95 103 10.1002/mus.21625 2-s2.0-77954129033
11. Nadjar Y., Gordon P., Corcia P., Bensimon G., Pieroni L., Meininger V., Salachas F., Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS ONE 2012 7 9 e45034 10.1371/journal.pone. 0045034 2-s2.0-84866400174
12. Ikeda K., Hirayama T., Takazawa T., Kawabe K., Iwasaki Y., Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Internal Medicine 2012 51 12 1501 1508 10.2169/internalmedicine.51.7465 2-s2.0-84862985282
13. Mizuno Y., Amari M., Takatama M., Aizawa H., Mihara B., Okamoto K., Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathologica 2006 112 5 597 603 10.1007/s00401-006-0122-4 2-s2.0-33749657635 (Pubitemid 44550683)
14. Goodall E. F., Greenway M. J., Van Marion I., Carroll C. B., Hardiman O., Morrison K. E., Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005 65 6 934 937 10.1212/01.wnl.0000176032. 94434.d4 2-s2.0-25444501340 (Pubitemid 41362146)
15. Restagno G., Lombardo F., Ghiglione P., Calvo A., Cocco E., Sbaiz L., Mutani R., Chiò A., HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. Journal of Neurology, Neurosurgery and Psychiatry 2007 78 3 327 10.1136/jnnp.2006.092338 2-s2.0-33847692753 (Pubitemid 46579679)
16. Sutedja N. A., Sinke R. J., van Vught P. W. J., van der Linden M. W., Wokke J. H. J., Van Duijn C. M., Njajou O. T., van der Schouw Y. T., Veldink J. H., van den Berg L. H., The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Archives of Neurology 2007 64 1 63 67 10.1001/archneur.64.1.63 2-s2.0-33846115578 (Pubitemid 46072425)
17. van Rheenen W., Diekstra F. P., van Doormaal P. T. C., Seelen M., Kenna K., McLaughlin R., Shatunov A., Czell D., van Es M. A., van Vught P. W. J., van Damme P., Smith B. N., Waibel S., Schelhaas H. J., van der Kooi A. J., de Visser M., Weber M., Robberecht W., Hardiman O., Shaw P. J., Shaw C. E., Morrison K. E., Al-Chalabi A., Andersen P. M., Ludolph A. C., Veldink J. H., van den Berg L. H., H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiology of Aging 2013 34 5 1517.e5 1517.e7 10.1016/j. neurobiolaging.2012.07.020 2-s2.0-84873479823
18. Blasco H., Vourc'H P., Nadjar Y., Ribourtout B., Gordon P. H., Guettard Y., Camu W., Praline J., Meininger V., Andres C. R., Corcia P., Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 2011 303 1-2 124 127 10.1016/j.jns.2010.12.018 2-s2.0-79952815816
19. Brooks B. R., Miller R. G., Swash M., Munsat T. L., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2000 1 5 293 299 10.1080/146608200300079536 2-s2.0-0034574407
20. Kimura F., Fujimura C., Ishida S., Nakajima H., Furutama D., Uehara H., Shinoda K., Sugino M., Hanafusa T., Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006 66 2 265 267 10.1212/01.wnl.0000194316.91908.8a 2-s2.0-33644910952 (Pubitemid 43970171)
21. Praline J., Blasco H., Vourc'h P., Rat V., Gendrot C., Camu W., Andres C. R., Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences 2012 317 1-2 58 61 10.1016/j.jns.2012.02.029 2-s2.0-84860295052
22. Zoccolella S., Beghi E., Palagano G., Fraddosio A., Guerra V., Samarelli V., Lepore V., Simone I. L., Lamberti P., Serlenga L., Logroscino G., Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry 2008 79 1 33 37 10.1136/jnnp.2007.118018 2-s2.0-37749045848
23. Marin B., Gil J., Preux P. M., Funalot B., Couratier P., Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotrophic Lateral Sclerosis 2009 10 4 216 220 10.1080/17482960902721626 2-s2.0-70249095561
24. Gordon P. H., Salachas F., Lacomblez L., Le Forestier N., Pradat P., Bruneteau G., Elbaz A., Meininger V., Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegenerative Diseases 2013 12 2 81 90 10.1159/000341316 2-s2.0-84881128873
25. Wijesekera L. C., Leigh P. N., Amyotrophic lateral sclerosis. Orphanet Journal of Rare Diseases 2009 4 1, article 3 10.1186/1750-1172-4-3 2-s2.0-62749193868
26. Hardiman O., Management of respiratory symptoms in ALS. Journal of Neurology 2011 258 3 359 365 10.1007/s00415-010-5830-y 2-s2.0-79953785573
27. Paillisse C., Lacomblez L., Dib M., Bensimon G., Garcia-Acosta S., Meininger V., Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2005 6 1 37 44 10.1080/14660820510027035 2-s2.0-18744385234 (Pubitemid 40668246)
28. Ince P. G., Shaw P. J., Candy J. M., Mantle D., Tandon L., Ehmann W. D., Markesbery W. R., Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neuroscience Letters 1994 182 1 87 90 10.1016/0304-3940(94)90213-5 2-s2.0-0027984081 (Pubitemid 24362029)
29. Kwan J. Y., Jeong S. Y., van Gelderen P., Deng H., Quezado M. M., Danielian L. E., Butman J. A., Chen L., Bayat E., Russell J., Siddique T., Duyn J. H., Rouault T. A., Floeter M. K., Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS ONE 2012 7 4 e35241 10.1371/journal.pone.0035241 2-s2.0-84859880865
30. Oshiro S., Morioka M. S., Kikuchi M., Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Advances in Pharmacological Sciences 2011 2011 378278 10.1155/2011/378278 2-s2.0-84555179169
31. Nappi A. J., Vass E., Iron, metalloenzymes and cytotoxic reactions. Cellular and Molecular Biology 2000 46 3 637 647 2-s2.0-0034182892
32. Kell D. B., Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology 2010 84 11 825 889 10.1007/s00204-010-0577-x 2-s2.0-78649444888
33. Hadzhieva M., Kirches E., Wilisch-Neumann A., Pachow D., Wallesch M., Schoenfeld P., Paege I., Vielhaber S., Petri S., Keilhoff G., Mawrin C., Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience 2013 230 94 101 10.1016/j.neuroscience.2012.11. 021 2-s2.0-84871533864
34. Wang Q., Zhang X., Chen S., Zhang X., Zhang S., Youdium M., Le W., Prevention of motor neuron degeneration by novel iron chelators in SOD1 G93A transgenic mice of amyotrophic lateral sclerosis. Neurodegenerative Diseases 2011 8 5 310 321 10.1159/000323469 2-s2.0-79958787596
35. Dixon S. J., Lemberg K. M., Lamprecht M. R., Skouta R., Zaitsev E. M., Gleason C. E., Patel D. N., Bauer A. J., Cantley A. M., Yang W. S., Morrison B. III, Stockwell B. R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012 149 5 1060 1072 10.1016/j.cell.2012.03.042 2-s2.0-84861541814
36. Pichler I., del Greco M. F., Gögele M., Lill C. M., Bertram L., Do C. B., Eriksson N., Foroud T., Myers R. H., Nalls M., Keller M. F., Benyamin B., Whitfield J. B., Pramstaller P. P., Hicks A. A., Thompson J. R., Minelli C., Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. PLoS Medicine 2013 10 6 e1001462 10.1371/journal.pmed.1001462 2-s2.0-84879529900
37. McCarthy R. C., Kosman D. J., Glial cell ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells. PLoS ONE 2014 9 2 e89003
38. Winkler E. A., Sengillo J. D., Sagare A. P., Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proceedings of the National Academy of Sciences of the United States of America 2014 111 11 E1035 E1042
39. Qureshi M., Brown R. H. Jr., Rogers J. T., Cudkowicz M. E., Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurology Journal 2008 2 51 54 10.2174/1874205X00802010051
40. Arosio P., Levi S., Ferritin, iron homeostasis, and oxidative damage. Free Radical Biology and Medicine 2002 33 4 457 463 10.1016/S0891-5849(02)00842- 0 2-s2.0-0037101879 (Pubitemid 34874967)
41. Velásquez Rodríguez C. M., Parra Sosa B., Morales Mira G., Agudelo Ochoa G., Cardona Henao O., Bernal Parra C., Burgos Herrera L., Betancur Acosta M., "Free" iron, transferrin and ferritin levels in serum and their relation with severe malnutrition. Anales de Pediatria 2007 66 1 17 23 10.1157/13097353 2-s2.0-33847771870 (Pubitemid 46391684)
42. Piskorz L., Lesiak T., Brocki M., Klimek-Piskorz E., Smigielski J., Misiak P., Jablonski S., Biochemical and functional indices of malnutrition in patients with operable, non-microcelullar lung cancer. Nutricion Hospitalaria 2011 26 5 1025 1032 10.3305/nh.2011.26.5.5170 2-s2.0-80052714111
43. Limousin N., Blasco H., Corcia P., Gordon P. H., De Toffol B., Andres C., Praline J., Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. Journal of the Neurological Sciences 2010 297 1-2 36 39 10.1016/j.jns.2010.06.028 2-s2.0-77956676420